Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093171 | 0.85 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HTTROCK1 | |
| SCHEMBL5720793 | 0.85 | ABCB1 (0.54) | ABCG2NPC1RAB9ASMN1; SMN2ROCK1 | |
| SCHEMBL28911671 | 0.83 | NAMPT (0.50) | NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4875132 | 0.82 | RAB9A (0.49) | ABCG2NPC1RAB9ASMN1; SMN2ROCK1 | |
| SCHEMBL25469660 | 0.78 | ABCG2 (0.52) | ABCG2 | |
| SCHEMBL4872174 | 0.77 | HCAR3 (0.63) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4876776 | 0.76 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10837371 | 0.76 | ROCK1 (0.59) | NPC1RAB9AROCK1 | |
| SCHEMBL22452903 | 0.76 | RAB9A (0.52) | ABCG2NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL17205695 | 0.75 | ABCG2 (0.47) | ABCG2NPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | ABCG2 3896/4885NPC1 4382/4885RAB9A 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.